#United States #San Diego #Gout Treatment #pozdeutinurad #Arthrosi

Arthrosi Showcases Long-Term Efficacy Data for Pozdeutinurad

Arthrosi Therapeutics Inc., a pioneering biotechnology firm, shared groundbreaking data regarding its novel drug, pozdeutinurad (formerly AR882), aimed at treating gout and tophaceous gout. The findings presented at the EULAR 2025 Congress in Barcelona highlight the drug's promising long-term safety and effectiveness.

Overview of Pozdeutinurad

Pozdeutinurad is a next-generation URAT1 inhibitor meticulously crafted to efficiently reduce serum urate (sUA) levels. Gout, known for its painful flare-ups and chronic symptoms, is characterized by uric acid crystallization within joints and soft tissues, leading to inflammation and discomfort. With an estimated 13 million individuals in the U.S. diagnosed with gout, the need for effective treatments is paramount.

Key Findings from the Phase 2 Trial

The Phase 2 trial extension focused on evaluating outcomes from long-term treatment, producing some compelling results:

• - Efficacy: The trials demonstrated that both monotherapy and combination therapy with pozdeutinurad resulted in a substantial and sustained decrease in sUA levels over 18 months.
• - Tophi Resolution: High rates of complete resolution of tophi—the deposits of uric acid crystals—were observed within a mere six months, significantly enhancing the quality of life for patients suffering from this chronic condition.
• - Safety Profile: The long-term administration of pozdeutinurad was found to be well-tolerated, showing no significant incidence of elevated serum creatine levels or liver function abnormalities, common concerns in urology treatments.

Clinical Implications and Future Directions

Robert T. Keenan, Chief Medical Officer at Arthrosi, emphasized the trial's importance, noting its potential to transform how gout is managed. The significant findings align with the company’s commitment to advancing pozdeutinurad through further clinical trials, including the fully enrolled Phase 3 REDUCE 2 global study, with additional patients rapidly enrolled in REDUCE 1.

Keenan stated, "The evident reduction in sUA over 18 months positions pozdeutinurad as a transformative best-in-class treatment for gout and tophaceous gout." The ongoing trials aim to solidify pozdeutinurad’s efficacy and safety, ultimately expanding treatment options for countless individuals affected by gout.

Conference Details and Presentations

At the EULAR 2025 Congress, two pivotal presentations on pozdeutinurad are set to unfold:

• - Poster Presentation: Titled Sustained Efficacy of Pozdeutinurad (AR882) focusing on its long-term effects on chronic gouty arthritis, scheduled for Saturday, June 14, 2025.
• - Oral Presentation: Entitled Safety and Tolerability of Pozdeutinurad (AR882) will delve into the chronic treatment safety, set for Friday, June 13, 2025.

Conclusion

Pozdeutinurad is showing remarkable promise within the realm of gout management. With established safety and efficacy data, its trajectory toward officially becoming a leading treatment option looks optimistic. As Arthrosi continues to gather data and move towards broader clinical trials, the medical community eagerly anticipates the full potential of this innovative therapeutic approach to gout.